Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington's disease

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD) are complex neurodegenerative disorders with diverse causes, including genetic and environmental factors.
• Current treatments for ALS and HD offer symptomatic relief but lack definitive cures, highlighting the need for novel therapeutic strategies.
• Gene therapy presents a promising avenue for neuroprotection and disease correction in neurodegenerative conditions.

Purpose of the Study:

• To provide a comprehensive review of antisense oligonucleotide (ASO) drug development for neurodegenerative diseases.
• To focus on the therapeutic strategies utilizing ASO drugs for amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD).
• To explore the mechanisms of action, limitations, and clinical applications of ASO-based therapies.

Main Methods:

• Literature review of preclinical and clinical studies on ASO drugs for ALS and HD.
• Analysis of the genetic targets and molecular mechanisms of ASO interventions.
• Evaluation of the efficacy and safety data from animal models and human clinical trials.

Main Results:

• ASO drugs targeting pathological genes in ALS and HD have demonstrated significant promise in numerous animal studies.
• Several clinical trials involving ASO therapies for these conditions have yielded encouraging results.
• ASO drugs represent a viable gene-based therapeutic approach for managing neurodegenerative diseases.

Conclusions:

• Antisense oligonucleotide (ASO) drugs are emerging as a powerful therapeutic tool for neurodegenerative diseases like ALS and HD.
• These gene-targeting therapies offer a potential pathway to modify disease progression beyond symptomatic management.
• Further clinical development and application of ASO drugs are crucial for advancing treatment options for patients with ALS and HD.